Loading clinical trials...

COMPLETEDPHASE2

Meaning-Centered Psychotherapy in Advanced Cancer

NCT00067288•National Center for Complementary and Integrative Health (NCCIH)

Summary

We have developed an 8-week Meaning-Centered Group Psychotherapy designed to help patients with advanced cancer sustain or enhance a sense of meaning, peace and purpose despite the limitations of their cancer illness. This project's overall aim is to explore the feasibility and efficacy of this new and unique psychotherapy intervention for advanced cancer patients in enhancing psychological and spiritual well-being and quality of life by comparing it with a standard supportive group psychotherapy.

Detailed Description

As per Brief Summary

Eligibility

Age

21 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•21 years of age or older;
•English speaking;
•Stage III or IV solid-tumor or Non-Hodgkin's Lymphoma;
•Receiving ambulatory care at Memorial Sloan-Kettering Cancer Center in New York City;

Exclusion Criteria

•Significant psychiatric disturbance sufficient, in the investigator's judgment, to preclude participation in a group-format intervention;
•Presence of cognitive impairment disorder, such as delirium or dementia that is sufficient, in the investigator's opinion, to preclude meaningful participation and/or informed consent;
•Karnofsky Performance Rating Scale below 50 or physical limitations or illness severity sufficient to preclude participation in outpatient group psychotherapy.

Locations (1)

Memorial Sloan-Kettering Institute for Cancer Research

New York, New York, United States

Key Dates

Start Date

May 1, 2002

Completion Date

March 1, 2006

Last Updated

August 18, 2006

Enrollment

118

Estimated participants

Conditions

Lymphoma, Non-HodgkinNeoplasms

Interventions

Meaning-Centered Group Psychotherapy

BEHAVIORAL

Standard Supportive Group Psychotherapy

BEHAVIORAL

A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer

NCT07169851

NauseaVomiting+2 more

View study

RECRUITINGPHASE3

A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer

NCT07213804

Ovarian NeoplasmsFallopian Tube Neoplasms+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 18, 2006Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Meaning-Centered Psychotherapy in Advanced Cancer

Inclusion Criteria

Exclusion Criteria

A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer

A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer

Post-operative Medium Chain Triglyceride Diet May Reduce Hospital Stay Following Lung Resection

Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease

Skin Conductance for Predicting Spinal Anesthesia-Induced Hypotension in Geriatric Urologic Oncology Patients

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer